Caldesmon regulates the motility of vascular smooth muscle cells by modulating the actin cytoskeleton stability

Qifeng Jiang1,2, Renjian Huang2, Shaoxi Cai*1 and Chih-Lueh A Wang* 2

Abstract

Background: Migration of vascular smooth muscle cells (SMCs) from the media to intima constitutes a critical step in the development of proliferative vascular diseases. To elucidate the regulatory mechanism of vascular SMC motility, the roles of caldesmon (CaD) and its phosphorylation were investigated.

Methods: We have performed Transwell migration assays, immunofluorescence microscopy, traction microscopy and cell rounding assays using A7r5 cells transfected with EGFP (control), EGFP-wtCaD or phosphomimetic CaD mutants, including EGFP-A1A2 (the two PAK sites Ser452 and Ser482 converted to Ala), EGFP-A3A4 (the two Erk sites Ser497 and Ser527 converted to Ala), EGFP-A1234 (both PAK- and Erk-sites converted to Ala) and EGFP-D1234 (both PAK- and Erk-sites converted to Asp).

Results: We found that cells transfected with wtCaD, A1A2 or A3A4 mutants of CaD migrated at a rate approximately 50% more slowly than those EGFP-transfected cells. The migration activity for A1234 cells was only about 13% of control cells. Thus it seems both MAPK and PAK contribute to the motility of A7r5 cells and the effects are comparable and additive. The A1234 mutant also gave rise to highest strain energy and lowest rate of cell rounding. The migratory and contractile properties of these cells are consistent with stabilized actin cytoskeletal structures. Indeed, the A1234 mutant cells exhibited most robust stress fibers, whereas cells transfected with wtCaD or A3A4 (and A1A2) had moderately reinforced actin cytoskeleton. The control cells (transfected with EGFP alone) exhibited actin cytoskeleton that was similar to that in untransfected cells, and also migrated at about the same speed as the untransfected cells.

Conclusions: These results suggest that both the expression level and the level of MAPK- and/or PAK-mediated phosphorylation of CaD play key roles in regulating the cell motility by modulating the actin cytoskeleton stability in dedifferentiated vascular SMCs such as A7r5.

Background

Migration of vascular smooth muscle cells (SMCs) from media to intima is a critical step in the development of proliferative vascular diseases such as atherosclerosis, and in response to vascular injuries such as angioplasty and organ transplantation. Fully differentiated SMCs normally do not proliferate nor migrate. Upon stimulation, however, SMCs can dedifferentiate and change from contractile to synthetic phenotypes, which enable cell proliferation and migration.

During this process SMCs undergo cellular remodelling and a number of smooth muscle-specific contractile proteins are converted to non-muscle isoforms. One of such signature proteins is caldesmon (CaD).

CaD is an actin-binding protein that also interacts with myosin, tropomyosin and calmodulin [1]. The two alternatively spliced isoforms of CaD derive from a single gene [2]: the heavy caldesmon (h-CaD), found exclusively in differentiated SMCs, and the light isoform (l-CaD), present in nearly all types of vertebrate cells. Unlike visceral smooth muscles, which only express h-CaD, vascular smooth muscles contain both h- (>75%) and l-CaD (<25%) [3]. However, upon dedifferentiation, h-CaD is rapidly degraded in vascular SMCs, and only l-CaD is expressed. Therefore, l-
CaD is the form that is closely associated with the synthetic type of smooth muscle organs.

Both h- and l-CaD bind actin filaments and stabilize the filamentous structure. In SMCs h-CaD, together with tropomyosin, modulates the actomyosin ATPase activity by reversibly and cooperatively inhibiting myosin binding to actin [4]. The inhibitory effect of h-CaD on muscle contractility has been demonstrated by peptide intervention [5-8] and antisense knockdown [9] experiments. Reversal of this inhibition is accompanied by phosphorylation of h-CaD at MAPK-specific sites [10], which partially dissociates h-CaD from actin filaments and allows myosin to bind [11]. The C-terminal region of h-CaD can also be phosphorylated by PAK [12] in vitro, although it is less clear whether or not the in vivo modification occurs in SMCs.

In non-muscle cells l-CaD appears to have more diverse functions. l-CaD has been reported to be involved in cell division [13], migration [14], adhesion [15], postmitotic spreading [16], apoptosis [17], and intracellular granule movement [18]. Like that of h-CaD, the action of l-CaD is also regulated via MAPK-mediated phosphorylation by such enzymes as cdc2 kinase [13] and Erk1/2 [14]. We have previously shown that, when cells are stimulated with phorbol ester, l-CaD is phosphorylated at the Erk sites and moves from stress fibers in the cytosol to nascent focal contacts at cell peripheries [16]. Phosphorylation of l-CaD by PAK also affects the morphology and migratory properties of non-muscle cells [19]. Consistently, l-CaD is present in podosomes [20,21], where it regulates podosome dynamics in a PAK-dependent manner [22].

The fact that the presumed functions of CaD are affected by MAPK and PAK has inspired much interest. Both types of kinases add phosphate groups to residues near the actin-binding sites at the C-terminal region of CaD, thereby decreasing its effectiveness of actin binding, as well as its stabilizing action on the actin cytoskeleton. This may suggest that CaD (particularly l-CaD) serves as a converging point for the MAPK and PAK signaling under the stimulation of a wide variety of agonists; it also raises the question as how the two types of CaD phosphorylation relate to each other. In this work we have analyzed the cellular consequences of the MAPK and PAK actions, individually and in combination, on l-CaD in a dedifferentiated SMC line (A7r5). By using phosphomimetic mutagenesis, we aimed to dissect the effect of MAPK- and PAK-mediated phosphorylation on CaD. Our results indicate that CaD phosphorylation is an obligatory step for cell motility, and that MAPK and PAK work independently and additively toward this process. Since only l-CaD is expressed in these cultured cells, CaD refers to the non-muscle isoform exclusively throughout this work except otherwise specified.

**Methods**

**Cell Culture**

Rat aorta smooth muscle cells A7r5 (ATCC# CRL-1444™) were maintained in DMEM (Cellgro™) supplemented with 10% fetal bovine serum (Cellgro™) and 1% antibiotics (Penicillin-Streptomycin, Cellgro™). Cells were cultured at 37°C under a 5% CO₂ atmosphere.

**Plasmids**

The pcB6 hx plasmid containing the cDNA of human l-CaD (GeneBank #M64110) was originally a gift from Dr. Jim Lin (University of Iowa, Iowa City, IA). The insert was subcloned into the mammalian expression vector pEGFPC1 (Clontech). Site-directed mutagenesis was performed as previously described [16] with the two PAK sites Ser452 and Ser482 converted to Ala (EGFP-A1A2); the two Erk sites Ser497 and Ser527 to Ala (EGFP-A3A4); both PAK- and Erk-sites to Ala (EGFP-A1234); or both PAK- and Erk-sites to Asp (EGFP-D1234).

**Cell Transfection**

A7r5 cells were plated at 60% confluence in 6-well cell culture plates. 18 h after plating, the cells were starved for 2 h before transfection using the Lipofectamine™ reagent supplemented with Plus™ reagent (Invitrogen). Briefly, 2 μg DNA in 5 μl Plus™ reagent and in 4 μl Lipofectamine™ reagent were diluted, respectively, with 43 μl and 46 μl serum-free DMEM medium. After 20 min incubation at room temperature, the two solutions were mixed and incubated for another 20 min. The mixture was then added to the cells; after 5 h the transfection medium was replaced with full medium.

**Western Blot Analysis**

The expression level of exogenous CaD induced by transfection, and the extent of CaD phosphorylation in A7r5 cells were evaluated by Western blot analysis using an Odyssey Infrared Imaging System by Li-COR Biosciences (Lincoln, NE) [23,24] as described previously [16]. Cells transfected with vehicle alone (EGFP), EGFP-wtCaD (wtCaD), EGFP-A1A2 (A1A2), EGFP-A3A4 (A3A4), EGFP-A1234 (A1234), or EGFP-D1234 (D1234) were seeded at 10⁵ cells/well on 6-well cell culture plates (Becton-Dickinson, Rutherford, NJ). After 24 h incubation, culture medium was removed, and cells were rinsed twice with ice-cold PBS. Proteins were extracted by adding to each well 150 μl of lysing buffer containing phenylmethylsulfonyl fluoride 1 mM (Sigma), leupeptin 10 μg/ml (Sigma), aprotin 30 μg/ml (Sigma), and NaVO₃ 1 mM (Sigma). The plates were incubated on ice for 30 min and scraped. Total cell extracts were separated on SDS-PAGE and immunoblotted with lab-made polyclonal anti-CaD and affinity purified polyclonal anti-pSer527 (Ser527 of l-CaD is equivalent to Ser789 in h-CaD), as well as monoclonal
anti-β-actin (Sigma), followed by affinity purified anti-rabbit and anti-mouse secondary antibodies conjugated with IRDyeTM 700 and 800, respectively. The digitized fluorescent bands were integrated, and the ratios (GFP-tagged CaD to endogenous CaD) were calculated for both protein level and phosphorylation of each pair after normalized against the amount of β-actin, which was used as a loading reference.

Fluorescence Microscopic Imaging
For fluorescence microscopy, cells transfected with EGFP, wtCaD, A1A2, A3A4, A1234, or D1234 were seeded on glass coverslips placed in a plastic culture dish and incubated overnight, during which time the cell became well-spread. Cells were then starved for 24 h and washed in PBS, fixed for 15 min in freshly prepared 4% paraformaldehyde (PFA) in PBS and permeabilized with 0.3% Triton X-100 in 4% PFA in PBS for 5 min. For all subsequent steps, solutions were prepared in PBS. Cells were thoroughly rinsed in PBS between steps and incubations were performed at room temperature. F-actin was stained with rhodamine-phalloidin and incubated for 1 h. Finally, cell-loaded coverslips were rinsed and mounted on glass slides in Mowiol (Sigma). Images were obtained using a laser scanning system BioRad Radiance 2000 equipped with the confocal head attached to the Nikon Eclipse TE300 microscope. Data were acquired and analyzed with Laser Sharp 2000 BioRad software. All images were collected through single-section acquisition with scan performed from the top to the bottom of the cell in two-color (green and red) channels in parallel.

Cell Migration Assay
Cell migration was assayed with 24-well tissue culture Transwell (Becton Dickinson) plates comprising a polycarbonate membrane with 8-μm pores. The inner and outer chamber membranes were coated with 5 μg/ml of human fibronectin (R&D, Minneapolis, MN) at 37°C for 2 h, and then rinsed with PBS. A7r5 cells transfected with EGFP, wtCaD, A1A2, A3A4, A1234, or D1234 were then seeded on the inner chamber of the Transwell plate at a concentration of 2 × 10⁴ cells/well in 200 μl serum-free DMEM. The inhibitory action of CaD on the actomyosin interaction is known to be regulated by MAPK- [11] and PAK- [12,19] mediated phosphorylation. To probe the significance of such regulation, to dissect the effect of the two types of phosphorylation, and to test their combined effect on the actin cytoskeleton and motility of SMCs, we have designed EGFP-tagged phosphomimetic mutants of CaD and force-expressed them in A7r5 cells. Serine residues at positions 452 (designated as position #1) and 482 (position #2) are taken as the "PAK-sites", whereas serines at positions 492 (position #3) and 527 (position #4) are taken as the "Erk-sites", which may also be phosphorylated by other MAPKs. Mutants include A1A2 (PAK-sites disabled), A3A4 (Erk-sites disabled), A1234 (both PAK- and Erk-sites disabled) and D1234 (both PAK- and Erk-sites phosphorylated).

Fourier-Transform Traction Microscopy
A7r5 cells transfected with EGFP, wtCaD, A1A2, A3A4, A1234, or D1234 were seeded on the collagen-coated, fluorescence microbeads-embedded polyacrylamide gel, which was prepared according to a previously described protocol [25,26], with the cell density kept lower than 10⁴ per dish. After 24 h incubation, the cells were starved overnight prior to measurements. With fluorescence channel first followed by phase-contrast, the image of a single green fluorescence cell and that of the fluorescent micropatterned beads were recorded before and after trypsinization. The two images of the micropatterned beads plus the phase-contrast cell image were taken to calculate the displacement field of the gel generated by the cell [27]. The projected cell area was also calculated based on the cell contour determined from the phase-contrast image obtained at the start of the experiment. From the displacement field the traction field within a 50 μm × 50 μm square was calculated as described by Butler et al. [28]. The magnitude and the direction of the vectors corresponding to the traction imposed on the gel underneath the cell yielded a scalar measure of cell contractility (strain energy), which is the total energy (in pJ) transferred from the cell to the substratum.

Cell Rounding Assays
Cell rounding assays after treatment with trypsin were performed as previously described [16].

Statistics
All measurements are expressed in terms of mean ± standard deviation (SD), except those of calculated total strain energy, which are expressed in mean ± standard error (SE). Comparisons between 2 samples of unequal variance were performed by Student's t-test using 2-tailed distribution. P < 0.05 was considered as significant.

Results
Effect of phosphomimetic mutation of CaD on the morphology of A7r5 cells
The inhibitory action of CaD on the actomyosin interaction is known to be regulated by MAPK- [11] and PAK- [12,19] mediated phosphorylation. To probe the significance of such regulation, to dissect the effect of the two types of phosphorylation, and to test their combined effect on the actin cytoskeleton and motility of SMCs, we have designed EGFP-tagged phosphomimetic mutants of CaD and force-expressed them in A7r5 cells. Serine residues at positions 452 (designated as position #1) and 482 (position #2) are taken as the "PAK-sites", whereas serines at positions 492 (position #3) and 527 (position #4) are taken as the "Erk-sites", which may also be phosphorylated by other MAPKs. Mutants include A1A2 (PAK-sites disabled), A3A4 (Erk-sites disabled), A1234 (both PAK- and Erk-sites disabled) and D1234 (both PAK- and Erk-sites phosphorylated).
Cells were also transfected with either EGFP-tagged wild-type CaD (wtCaD) or the vehicle alone (EGFP), the latter being used as controls. The cell viability was not appreciably affected by transient transfection. No sign of cell death was detected within the time period of experimentation.

Among all constructs transfected with the A1234 mutant showed most robust cytoskeleton structure. The majority of A1234-expressing cells exhibited thicker and longer stress fibers than the untransfected cells and the EGFP-expressing control cells. The green fluorescence in these cells overlapped closely with the red phallolidin staining (Fig. 1-c), indicating that the expressed CaD mutant binds to the actin cytoskeleton with augmented stability. The wtCaD, A1A2 and A3A4 transfected cells also showed prominent cytoskeleton structures with similar overlapping distribution of EGFP-tagged CaD with stress fibers (Fig. 1-a,b,f), but the difference between transfected cells and untransfected cells was less striking than that for A1234. In contrast, the D1234-transfected cells exhibited much weaker stress fiber staining than cells transfected with the A-mutants and wt-CaD. Although some faint stress fibers were nevertheless detected in D1234-transfected cells, the exogenous CaD primarily overlapped with the F-actin staining at the cortical regions. Notably, the actin cytoskeleton in these cells exhibited little or no difference from that in the untransfected cells, as seen in the control cells (Fig. 1-d,e).

**Effect of phosphomimetic mutation of CaD on the motility of A7r5 cells**

To determine the effect of phosphomimetic mutation of CaD on the motility of A7r5 cells, we have performed Boyden chamber migration assays using Transwell filters of 8-μm pore size. Cells were stimulated by 50 ng/ml FGF and 10% serum to undergo chemotactic migration. The motility of cells expressing different CaD mutants relative to the normal, untransfected cells was evaluated after 36 hours. Among all constructs the A1234 mutant resulted in most hindered motility. Taking untransfected A7r5 cells as a standard, we found that the relative migration activity for the A1234-transfected cells was only 0.113 ± 0.02 (n = 3; same below), which was about 13% of the EGFP-transfected control cells (0.85 ± 0.07; Fig. 2). Transfection with wtCaD also slowed down the rate of cell migration, but to a lesser extent (0.417 ± 0.07 pJ). Both the A1A2 (1.81 ± 0.39 pJ) and A3A4 (1.60 ± 0.40 pJ) mutants resulted in about 8-fold enhancement in total strain energy. The wtCaD transfected cells also had significantly higher traction force than the control cells, although not as high as the A1234 mutant transfected cells. The increases in the contractility caused by the wtCaD transfection were about 6-fold (1.23 ± 0.24 pJ). The D1234 mutant transfected cells showed severely hampered motility (see Fig. 2), exhibited most strengthened, instead of compromised, contractility, among all CaD variant transfected cells (Fig. 3B). The A1234 mutant (3.08 ± 0.22 pJ) showed about 15-fold enhancement in the traction force measurement compared to the control cells (0.21 ± 0.07 pJ). Both the A1A2 (1.81 ± 0.39 pJ) and A3A4 (1.60 ± 0.40 pJ) mutants resulted in about 8-fold enhancement in total strain energy. The wtCaD transfected cells also had significantly higher traction force than the control cells, although not as high as the A1234 mutant transfected cells. The increases in the contractility caused by the wtCaD transfection were about 6-fold (1.23 ± 0.24 pJ). The D1234 mutant transfection showed little enhancement for cell contractility, the measured force for the D1234 mutant transfected cells (0.44 ± 0.13 pJ) was almost the same as that of the control cells. It should be mentioned that because the traction measurements were based on single cell experiments, the scattering of the data was relatively large even with multiple measurements for each set (n = 10). Nevertheless, from the trend of the data it is rather striking that the effect of phosphomimetic CaD transfection on the contractility is precisely reciprocal to that on the migratory activity: The cells with the highest migratory activity (i.e., the EGFP-expressing cells) showed the lowest strain...
**Figure 1** (See figure legend on next page.)
nergy, whereas the cells with the slowest migration (i.e., the A1234-expressing cells) had the strongest strain energy. Like in the case of migration assays, the PAK- (A1A2) or Erk- (A3A4) sites disabled mutants exhibited about 50% of the change displayed by the mutant with both types of phosphorylation sites disabled (A1234). Phosphorylation of CaD therefore must have similar but opposite effects on these two events. Another important finding from these data is that, since the strain energy results from actin-based contractile force, the observed lower migration activity of mutated A7r5 cells clearly was not owing to inhibited contractility.

State of phosphorylation of CaD mutants by Western blot analysis

The fact that cells expressing the A1A2 and the A3A4 mutants exhibited about 50% of the overall changes found for the A1234 cells in both migration and contractile activities compared to those of the control cells implies: (a) PAK- and MAPK-mediated phosphorylation of CaD contributes equally and additively to these activities; and (b) the A1A2 and the A3A4 mutants might in fact be phosphorylated at other available sites in these cells. To test the latter idea, we have examined the phosphorylation status of the engineered CaD mutants by Western blot analysis. A lab-prepared polyclonal antibody against the Erk-site pSer527 (or pSer789 in h-CaD) was used for this purpose. Indeed, as shown in Fig. 4, the EGFP-tagged A1A2 and wtCaD, but not the A3A4 and A1234, were found positive for MAPK-mediated phosphorylation. Not surprisingly, the endogenous CaD in all cell lines was also phosphorylated at this Erk-site. Since we don't have the anti-PAK-sites antibody, a similar experiment to verify the PAK-mediated phosphorylation...
Figure 3 (A) Fourier transform traction microscopy measurements and the images of a representative A7r5 cell gathered in the measurement process. (a) The single green cell was first identified under fluorescence channel and then the phase-contrast image (upper right) was recorded. Based on beads movement, the traction field was calculated by MATLAB. The magnitude and the direction of the vectors indicate the bead movement, which was used to compute the contractile moment. Scale bar: 50 μm. (b) The color coding for the magnitude of the bead movement. (B) Results of total strain energy measurements (in pJ) of A7r5 cells transfected with phosphomimetic mutants of CaD and EGFP alone (control). The error bars represent the standard errors (SE) of 10 measurements. Single (*) and double (**) asterisks on the peaks denote $P < 0.05$ and $P < 0.005$, respectively.
ation on the EGFP-tagged CaD variants is not possible at this time.

**Effect of phosphomimetic mutation of CaD on the detachment behavior of A7r5 cells upon trypsinization**

Finally, in search of the cause for the decreased migration activity, we wished to test whether CaD mutation affects cell detachment, which constitutes another step critical to cell migration. Cells undergo rapid retraction and rounding, and eventual detachment from the substratum upon trypsin treatment because of disengagement of focal adhesions and partial disassembly of actin bundles. We used a simple assay by quantifying the number of rounded cells (including detached cells) as a function of time following trypsinization to compare the detachment kinetics of A7r5 cells transfected with either EGFP or CaD mutants. We found that cells transfected with wtCaD, A1A2 or A3A4 all showed delayed responses to trypsin digestion as compared to the control cells (Fig. 5). Even more hampered rounding was observed for the A1234 transfected cells, in agreement with previous observations with rat aortic fibroblast cells [16]. In contrast, the D1234 transfected cells showed similar kinetics of rounding up as the control cells. The detachment behavior thus parallels the migration activity.

**Discussion**

CaD is known to bind actin and stabilize the filamentous structure. Binding of CaD to actin also inhibits the actomyosin interaction, and results in inhibition on many cellular processes such as migration, adhesion and proliferation [30]. These inhibitory actions can be reversed by binding to calmodulin in the presence of Ca²⁺, although it is more likely that the in vivo function of CaD is regulated by phosphorylation. In vivo CaD phosphorylation was documented not only in activated SMCs [31], but also in mitotic cells [32] and migrating smooth muscle [14] or non-muscle cells [16]. Because of these properties, CaD serves as a target for manipulation of cellular behaviors. There have been plenty of data in the literature using ectopic expression of CaD or mutants to probe cell movement; however, the results are not always consistent [16,17,20,33-38]. While most studies found over-expressed CaD stabilizes stress fibers in the cell and inhibits cell motility, one report [37] showed opposite results, in which case transient transfection of CaD not only disrupted stress fibers, but also disassembled focal adhesions. Because of this controversy, the exact function of CaD has not been settled, although the critical involvement of CaD in cell motility is widely recognized.

Notably, in that earlier study the phosphorylation status of CaD was not determined. In light of the findings that unphosphorylated and phosphorylated CaD display quite different actin-binding properties [11,39] and intracellular distributions [16,21], variations in CaD phosphorylation may have contributed to this apparent discrepancy. To better understand the role of CaD phosphorylation in vascular SMCs, we have force-expressed phosphomimetic mutants of CaD in A7r5 cells, a model for remodelled or diseased vascular SMCs, and examined the resulting cells in terms of their morphology, migration activity, contractility and detachment kinetics. We focused on Erk and PAK by separately or simultaneously altering the residues of the respective modification sites, because both kinases have previously been shown to affect CaD's affinity for actin filaments. Our data indicated that in order for A7r5 cells to attain motility, phosphorylation of CaD by either kinase is an obligatory step, primarily through the modulation of the actin cytoskeleton dynamics, rather than the contractile machinery of the cell.

**Figure 4 Western blot analysis of CaD phosphorylation in the transfected A7r5 cells**

The total cell extracts from A7r5 cells transfected with various constructs were immunoblotted with polyclonal anti-pSer527 (Left Panel) and anti-CaD (Right Panel) antibodies. M: Molecular weight markers; samples (Lanes 2-6) are, respectively, cells transfected with A1A2, A3A4, A1234, wtCaD, and EGFP alone (Control). The corresponding ratios of the digitized intensity of the EGFP-tagged CaD variant (the upper red band; Right Panel) to that of the endogenous CaD (the lower red band; Right Panel) are, respectively, 0.93, 1.71, 2.60, 0.43 and 0 (EGFP); and the corresponding ratios of the digitized intensity of the phospho-EGFP-CaD variant (the upper red band; Left Panel) to that of the phosphorylated endogenous CaD (the lower red band; Left Panel) are, respectively, 0.13 (A1A2), 0, 0, 0.10 (wtCaD) and 0. The apparent lower signal in the phosphorylation for the engineered variants (human) than the endogenous CaD (rat) may be partly due to different immuno-reactivities of the antibodies. Moreover, since the transfection efficiency is ~35% in all cases, the actual ratios could be higher.
The phosphorylation-disabled CaD mutant, A1234, at both PAK- and Erk-sites hampered the migration activity to the greatest extent (to ~13% of the control cells; Fig. 2). Cell migration is a multiple-step process, which includes cell extension, attachment, contraction and rear detachment [29]. The observed slower migration could have resulted from one or more compromised steps in this process. However, when we examined the cell contractility by traction microscopy, we found that the A1234-expressing cells exhibited strongest traction force (Fig. 3B). Thus the overall cell motility must be dominated by step(s) other than contraction. Indeed, the detachment assay showed that A1234 mutant rendered A7r5 cells to round up and detach from the substratum more slowly than other variants (Fig. 5). Consistent with this observation is the fact that cells transfected with A1234 exhibited most robust stress fibers (Fig. 1). It is conceivable that these structures may be hard to disassemble. Together, these results suggest that it is the less dynamic actin cytoskeleton, which is overly stabilized by the unphosphorylatable CaD, that makes the cell more resistant to shape changes, and thereby hampering the cell motility. This interpretation agrees with Yamashiro’s work [40], and reinforces our understanding about the functional role of CaD phosphorylation as a means to reverse the actin stabilizing effect of CaD.

The fact that Ser-to-Ala mutation at only four positions (amino acid residue-452, 482, 497 and 527) attains a reduction in cell motility of nearly 90% is quite remarkable. On one hand, it means phosphorylation at these four residues is necessary for cell migration, on the other hand, it also demonstrates that other mechanisms including phosphorylation at other positions only contribute no more than 13% of the overall migration activity. Previously, it has been suggested that Ca²⁺/calmodulin also regulates the CaD-imposed inhib-
ity effect [41]; our results argue that such an effect may only play a minor role in A7r5 cells, particularly in the absence of phosphorylation-mediated regulation. Transfection with A1A2 or A3A4 mutants of CaD inhibited approximately 50% of the extent by the A1234 mutant in cell migration when compared to the control cells (Fig. 2). This intermediate activity could be due to phosphorylation at residues that remain available. Indeed, Ser-527 (one of the Erk-sites) of the A1A2 mutant was found to be phosphorylated (Fig. 4). Thus it seems both MAPK and PAK contributed equally and additively to the overall motility of cultured aorta SMCs. The involvement of PAK, which is a downstream effector of Rac signaling, in cell migration is well established. That MAPK-mediated phosphorylation also enables cell migration is consistent with previous observations [14], and suggests the existence of cross-talks between MAPK- and PAK-pathways.

Force-expression of wild-type CaD (in wtCaD cells) decreased the motility of the A7r5 cells. This may be understood by the assumption that the total CaD level in these cells exceeds the capacity of the kinases and results in a net increase of unphosphorylated CaD, which causes inhibition of the cell motility. This situation is similar to that of the A1A2 and A3A4 cells, where phosphorylation of CaD is partially blocked. This interpretation is supported by the observation that these three types of cells exhibited about the same degree of suppression in motility. When we force-expressed D1234 mutant, we expected an increase in the motility, because the phospho-mimicking mutation might represent a scenario opposite to the fully inhibited state (e.g., A1234). Yet we found the D1234 mutant also suppressed the motility of the cells, although to a lesser extent (~24% inhibited). This could be attributed to the fact that such modification was irreversible. Not being able to dephosphorylate, this CaD mutant disrupts the phosphorylation cycling of endogenous CaD and may thereby lead to inhibition of cell motility [19]. In the meantime, since D1234 mutant has a much weakened affinity for the actin filament, it cannot stabilize the cytoskeleton as much as A1234 or wt-CaD; so the D1234 mutant cells showed weaker stress fiber structure and similar contractility and detachment behaviors compared to the control cells.

Our data indicate that the migratory activity of cells changes in a reciprocal manner as the contractility of the cells, despite that contraction is an essential step during cell migration. The contractile activity, as evaluated by our assays based on the total strain energy the cell exerts on the substratum, requires active actomyosin interactions. However, an equally important factor is a sturdy cytoskeleton structure that provides a framework for such interactions and supports the contractility. Without firm actin cables, such as in the D1234-transfected cells, even a relatively high actomyosin ATPase activity would not be able to generate force. The cell contractility, the cytoskeleton stability, and the cell migration activity must therefore behave in a coordinated manner. On the other hand, the A1234-expressing cells, which produced highest traction force because of the stabilized actin cytoskeleton therein, must also have an actomyosin activity that is not severely inhibited. This is rather surprising in view of the overwhelming evidence that unphosphorylated CaD (i.e., A1234) inhibits such activity. One possible explanation is that the actomyosin interaction is activated through the binding of calmodulin to CaD, as the calmodulin-binding sites are still functional in these mutants. However, this mechanism apparently fails to restore the migration activity, since cells expressing A1234 were only 13% as motile as the control cells (Fig. 2). Clearly, the cytoskeleton stability is a more dominant factor than the actomyosin ATPase activity in the case of cell migration, because multiple steps (i.e., extension, attachment and detachment) in this process depend on the ability of actin filaments to be assembled and disassembled dynamically.

The finding that stabilization of the actin cytoskeleton by CaD is critical for cell motility provides the rationale for using CaD to curb SMC migration which in most cases is pathogenic. In particular, transfection of CaD in mice has been shown to suppress the growth of vascular SMCs and inhibit neointimal formation after angioplasty [42]. More recently it was reported that expression of CaD suppresses the invasive activity of cancer cells [43]. Our study further suggests that CaD with combined mutations at both PAK- and Erk-sites (e.g., A1234) may serve as a more effective therapeutic reagent in cancer and proliferative vascular diseases such as atherosclerosis and restenosis.

**Conclusions**

In this study we showed that CaD suppresses the motility of vascular SMCs by stabilizing the actin filamentous structure. Despite intensive studies over the past three decades, the functional role of CaD in non-muscle cells remains elusive. In this regard, our data shed light onto the following aspects: (1) Phosphorylation of CaD at the Erk- and PAK-sites near the actin-binding sites of CaD is required for cell motility, because it reverses CaD’s inhibitory effect and allows dynamic changes of the actin cytoskeleton. (2) Both Erk and PAK contribute equally and additively toward this regulatory role in cell migration and contraction. (3) Other mechanisms such as phosphorylation at residues other than the four positions (residues 452, 482, 497 and 527) or interaction with calmodulin only play a relatively minor role in modulating the motility of A7r5 cells. These new insights not only help us to better understand how CaD works, but also afford useful information on how cell motility is regulated. For SMCs, in particular, our findings suggest that mutations at CaD phosphorylation sites serve as a novel therapeutic strategy to combat vascular diseases such as atherosclerosis and restenosis.
List of abbreviation used
CaD: caldesmon; Erk: extracellular signal-regulated kinase; FGF: fibroblast growth factor; h-CaD: heavy or smooth muscle-specific caldesmon; l-CaD: light or non-muscle caldesmon; MAPK: mitogen-activated protein kinase; PAK: p21-activated protein kinase; PBS: phosphate buffered saline; PFA: paraformaldehyde; SMC: smooth muscle cell.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
QJ participated in the design of the study. CLAW conceived of the study, and participated in its design and coordination of the experiments, and helped to write the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors wish to thank Ms. Lijia Zhu for technical assistance, Dr. Julanta Kordowska for helpful discussion at the early phase of this project, and Dr. Chan Young Park and Professor Jeffrey Fredberg (of Harvard School of Public Health) for their help in performing and analyzing the traction microscopic measurements. This study was supported by a grant (No 10872224 to SC) from Chinese National Natural Science Foundation and "111" project, and a grant (R01 HL92252 to CLAW) from NIH.

Author Details
1Key Laboratory of Biochemical Science and Technology, Ministry of Education, Bioengineering College, Chongqing University, Chongqing, 400044, China and 2Boston Biomedical Research Institute, 64 Grove St, Watertown, MA 02472, USA

Received: 29 October 2009 Accepted: 3 February 2010
Published: 3 February 2010

References
1. Wang C-LA: Caldesmon and smooth-muscle regulation. Cell Biochem Biophys 2001, 35(3):275-288.
2. Humphrey MB, Herrera-Sosa H, Gonzalez G, Lee R, Bryan J: Cloning of cDNAs encoding human caldesmons. Gene 1992, 112(19):207-214.
3. Glukhova MA, Kabakov AE, Frid MG, Omratsky OJ, Bellen AM, Mulkhin DN, Orekhov AN, Koteliansky VE, Smirnov VN: Modulation of human aortic smooth muscle cell phenotype: a study of muscle-specific variants of caldesmon, actin, and alpha expression. Proc Natl Acad Sci USA 1988, 85(24):9542-9546.
4. Wang CL: Caldesmon and the Regulation of Cytoskeletal Functions. Adv Exp Med Biol 2008, 644:250-272.
5. Lajie CA, Parker CA, Wang CL, Morgan KG: Loading of caldesmon peptide (GS17C) into intact vascular smooth muscle by reversible permeabilization. Biophys J 1994, 66:4408.
6. Katsuyama H, Wang CL, Morgan KG: Regulation of vascular smooth muscle tone by caldesmon. J Biol Chem 1992, 267(21):14555-14558.
7. Lee YH, Gallant C, Guo H, Li Y, Wang CL, Morgan KG: Regulation of vascular smooth muscle tone by N-terminal region of caldesmon. Possible role of tethering actin to myosin. J Biol Chem 2000, 275(23):2132-320.
8. Hulvershorn J, Gallant C, Wang CL, Dessy C, Morgan KG: Calmodulin levels are dynamically regulated in living vascular smooth muscle cells. American Journal of Physiology - Heart & Circulatory Physiology 2001, 280(3):H1422-H1426.
9. Earley JJ, Su X, Moreland RS: Caldesmon inhibits active cytoskeletons in unstimulated vascular smooth muscle: an antisense oligodeoxynucleotide approach. Circ Res 1998, 83(6):661-667.
10. Adam LP, Gapisinski CJ, Hathaway DR: Phosphorylation sequences in h-caldesmon from phorbol ester-stimulated canine aortas. FEMS Lett 1992, 302(3):223-226.
11. Huang R, Li L, Guo H, Wang CL: Caldesmon binding to actin is regulated by calmodulin and phosphorylation via different mechanisms. Biochemistry 2003, 42(9):2513-2523.
12. Foster DB, Shen LH, Kelly J, Thibault P, Van Eyk JE, Mak AS: Phosphorylation of caldesmon by p21-activated kinase. Implications for the Ca(2+)/calmodulin sensitivity of smooth muscle contraction. J Biol Chem 2000, 275(3):1959-1965.
13. Yamashiro S, Yamakita Y, Hosoya H, Matsumura F: Phosphorylation of non-muscle caldesmon by p34cdc2 kinase during mitosis. Nature 1991, 349(6308):169-172.
14. Yambolie IA, Gerhoffer WT: Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. American Journal of Physiology - Cell Physiology 2001, 280(6):C1680-C1688.
15. Haxhinasto KB, Kamath AM, Blackwell K, Zabner J, Lin J, Moy AB: The effects of caldesmon on fibroblast cell adhesion and motility. Mol Biol Cell 2002, 13:3114a.
16. Kordowska J, Hetrick T, Adam LP, Wang CL: Phosphorylated l-caldesmon is involved in disassembly of actin stress fibers and podomtotic spreading. Exp Cell Res 2006, 312(2):95-110.
17. Numauchi Y, Huang S, Polte TR, Echler GS, Wang N, Ingber DE: Caldesmon-dependent switching between capillary endothelial cell growth and apoptosis through modulation of cell shape and contractility. Angiogenesis 2003, 6(1):65-64.
18. Hegmann T, Schulte DL, Lin J, Lin J: Inhibition of intracellular granule movement by microinjection of monoclonal antibodies against caldesmon. Cell Motol Cytokeleton 1991, 20(2):109-120.
19. Eppinga RD, Li Y, Lin J, Mak AS, Lin J: Requirement of reversible caldesmon phosphorylation at P21-activated kinase-responsive sites for lamellipodia extensions during cell migration. Cell Motol Cytokeleton 2006, 63(9):543-562.
20. Eves R, Webb BA, Zhou S, Mak AS: Caldesmon is an integral component of podosomes in smooth muscle cells. J Cell Sci 2006, 119(Pt 9):1691-1702.
21. Gu Z, Kordowska J, Williams GL, Wang CL, Hai CM: Erk1/2 MAPK and caldesmon differentially regulate podosome dynamics in A7r5 vascular smooth muscle cells. Exp Cell Res 2007, 313(5):849-866.
22. Morita T, Mayanagi T, Yoshio T, Sobe K: Changes in the balance between caldesmon regulated by P21-activated kinases and the Arp2/3 complex govern podosome formation. J Biol Chem 2007, 282(11):8454-8463.
23. Snapyan M, Lecocq M, Guevel L, Amaud MC, Ghochikyan A, Sakanyan V: Dissecting DNA-protein and protein-protein interactions involved in bacterial transcriptional regulation by a sensitive protein array method combining a near-infrared fluorescence detection. Proteomics 2003, 3(5):647-657.
24. Grosch S, Tegeder I, Schilling K, Maier TJ, Niederberger E, Geisslinger G: Activation of c-Jun-N-terminal kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers, Faseb J 2003, 17(10):1316-1318.
25. Dembo M, Wang YL: Stresses at the cell-to-substrate interface during locomotion of fibroblasts. Biophys J 1999, 76(4):2307-2316.
26. Wang N, Tolic-Norrelykke IM, Chen J, Mijailovich SM, Butler JP, Fredberg JJ, Stamenovic D: Cell protrust. Siftness and protrust are closely associated in adherent contractile cells. Am J Physiol Cell Physiol 2002, 283(3):C606-616.
27. Tolic-Norrelykke IM, Butler JP, Chen J, Wang N: Spatial and temporal traction response in human airway smooth muscle cells. American journal of physiology 2002, 283(4):1254-1266.
28. Butler JP, Tolic-Norrelykke IM, Fabry B, Fredberg JJ: Traction fields, moments, and strain energy that cells exert on their surroundings. Am J Physiol Cell Physiol 2002, 283(3):C595-605.
29. Condeelis J: The biochemistry of animal cell crawling. In Motion Analysis of Living Cell New York: Wiley-Liss; 1998:65-100.
30. Lin J, Li Y, Eppinga RD, Wang Q, Lin J: Chapter 1: roles of caldesmon in cell motility and actin cytoskeleton remodeling. Int Rev Cell Mol Biol 2009, 274:1-68.
31. Adam LP, Haebeler JR, Hathaway DR: Phosphorylation of caldesmon in arterial smooth muscle. J Biol Chem 1989, 264(13):7698-7703.
32. Yamashiro S, Yamakita Y, Ishikawa R, Matsumura F: Mitosis-specific phosphorylation causes B3K non-muscle caldesmon to dissociate from microfilaments. Nature 1996, 344(6267):675-678.
33. Warren KS, Shutt DC, McDermott JP, Lin JL, Soll DR, Lin JJ: Overexpression of microfilament-stabilizing human caldesmon fragment, CaD39, affects cell attachment, spreading, and cytokinesis. Cell Motil Cytoskeleton 1996, 34(3):215-229.

34. Li Y, Wessels D, Wang T, Lin JL, Soll DR, Lin JJ: Regulation of caldesmon activity by Cdc2 kinase plays an important role in maintaining membrane cortex integrity during cell division. Cell Mol Life Sci 2003, 60(1):198-211.

35. Surgucheva I, Bryan J: Over-expression of smooth muscle caldesmon in mouse fibroblasts. Cell Motil Cytoskeleton 1995, 32(3):233-243.

36. Mirzapoiazova T, Kolosova IA, Romer L, Garcia JG, Verin AD: The role of caldesmon in the regulation of endothelial cytoskeleton and migration. J Cell Physiol 2005, 203(3):520-528.

37. Helfman DM, Levy ET, Berthier C, Shwutman M, Riveline D, Grosheva I, Lachish-Zalait A, Elbaum M, Bershadsky AD: Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions. Mol Biol Cell 1999, 10(10):3097-3112.

38. Grosheva I, Vittitow JL, Goichberg P, Gabelt BT, Kaufman PL, Borras T, Geiger B, Bershadsky AD: Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. Exp Eye Res 2006, 82(6):945-958.

39. Foster DB, Huang R, Hatch V, Craig R, Graceffa P, Lehman W, Wang C-LA: Modes of caldesmon binding to actin: sites of caldesmon contact and modulation of interactions by phosphorylation. J Biol Chem 2004, 279(51):53387-53394.

40. Yamashiro S, Chern H, Yamakita Y, Matsumura F: Mutant caldesmon lacking cdcl2 phosphorylation sites delays M-phase entry and inhibits cytokinesis. Molecular Biology of the Cell 2001, 12(1):239-250.

41. Li Y, Lin JL, Reiter RS, Daniels K, Soll DR, Lin JJ: Caldesmon mutant defective in Ca2+-calmodulin binding interferes with assembly of stress fibers and affects cell morphology, growth and motility. J Cell Sci 2004, 117(Pt 16):3593-604.

42. Yokouchi K, Numaguchi Y, Kubota R, Ishii M, Imai H, Murakami R, Ogawa Y, Kondo T, Okumura K, Inagber DE, Murakasa T, I-Caldesmon regulates proliferation and migration of vascular smooth muscle cells and inhibits neointimal formation after angioplasty. Arterioscler Thromb Vasc Biol 2006, 26(10):2231-2237.

43. Yoshio T, Morita T, Kimura Y, Tsujii M, Hayashi N, Sobue K: Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation. FEBS Lett 2007, 581(20):5777-5782.

doi: 10.1186/1423-0127-17-6
Cite this article as: Jiang et al., Caldesmon regulates the motility of vascular smooth muscle cells by modulating the actin cytoskeleton stability Journal of Biomedical Science 2010, 17:6